{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Mutations&page=7", "query": { "condition": "Genetic Mutations", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 941, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Mutations&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Mutations&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T12:38:12.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02823470", "title": "A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "LUM/IVA", "type": "DRUG" }, { "name": "activated smart device", "type": "DEVICE" }, { "name": "de-activated smart device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 24, "start_date": "2016-06", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2018-09-27", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 7, "location_summary": "Hartford, Connecticut • Washington D.C., District of Columbia • Orlando, Florida + 4 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823470" }, { "nct_id": "NCT01567046", "title": "Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Childhood Alveolar Soft-part Sarcoma", "Childhood Angiosarcoma", "Childhood Desmoplastic Small Round Cell Tumor", "Childhood Epithelioid Sarcoma", "Childhood Fibrosarcoma", "Childhood Leiomyosarcoma", "Childhood Liposarcoma", "Childhood Malignant Mesenchymoma", "Childhood Neurofibrosarcoma", "Childhood Synovial Sarcoma", "Chordoma", "Desmoid Tumor", "Metastatic Childhood Soft Tissue Sarcoma", "Nonmetastatic Childhood Soft Tissue Sarcoma", "Recurrent Childhood Soft Tissue Sarcoma" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 70, "start_date": "2016-05", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 1, "location_summary": "Monrovia, California", "locations": [ { "city": "Monrovia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01567046" }, { "nct_id": "NCT04019327", "title": "A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma", "Prostate Neoplasm", "Prostate Cancer Metastatic", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2019-07-11", "completion_date": "2025-12-04", "has_results": true, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 9, "location_summary": "Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019327" }, { "nct_id": "NCT02724527", "title": "Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-04", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2016-11-21", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 12, "location_summary": "Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724527" }, { "nct_id": "NCT03140969", "title": "Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leber's Congenital Amaurosis" ], "interventions": [ { "name": "QR-110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laboratoires Thea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 11, "start_date": "2017-10-16", "completion_date": "2019-10-02", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03140969" }, { "nct_id": "NCT02091141", "title": "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Solid Tumors", "Biliary Cancer", "Salivary Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2014-04-14", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 60, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091141" }, { "nct_id": "NCT02644122", "title": "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma" ], "interventions": [ { "name": "SF1126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ezra Cohen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-11", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02644122" }, { "nct_id": "NCT00001927", "title": "Study of Abnormal Blood Clotting in Children With Stroke", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Abnormalities", "Blood Coagulation Disorder", "Brain Disease", "Cerebrovascular Accident", "Vascular Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 130, "start_date": "1999-02-22", "completion_date": "2011-05-04", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001927" }, { "nct_id": "NCT00803205", "title": "Study of Ataluren (PTC124™) in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ataluren", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 238, "start_date": "2009-09-08", "completion_date": "2011-11-12", "has_results": true, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Long Beach, California • Palo Alto, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803205" }, { "nct_id": "NCT07237100", "title": "Mirdametinib in Patients With Advanced NF1-mutant Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Kim, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-10-13", "completion_date": "2030-10-13", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-30T12:38:12.199Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07237100" } ] }